International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

Mast, T. Christopher; Kierstead, Lisa; Gupta, Swati; Nikas, Alexander; Kallas, Esper G.; Novitsky, Vladimir; Mbewe, Bernard; Pitisuttithum, Punee; Schechter, Mauro; Vardas, Eftyhia; Wolfe, Nathan; Aste-Amézaga, Miguel; Casimiro, Danilo R.; Coplan, Paul; Straus, Walter L.; Shiver, John W.

doi:10.1016/j.vaccine.2009.10.145

Cited by 255 publications

(239 citation statements)

References 34 publications

Supporting

Mentioning

217

Contrasting

Order By: Relevance

“…With regard to AdV, a great majority of children are supposed to be protected against the virus, because of maternal Ig transmission in infants, followed by early natural immunization from 1 to 2 y of age (14). In agreement, in the 0 -2 y group, the mean percentage of CD4-secreting IFN␥ following stimulation with AdV (0.10%) was not significantly different from background (unstimulated cultures; 0.05%).…”

Section: Dynamic Changes In the Proportion Of Cd4mentioning

confidence: 58%

See 1 more Smart Citation

Development of Cytomegalovirus and Adenovirus-Specific Memory CD4 T-Cell Functions From Birth to Adulthood

et al. 2011

View full text Add to dashboard Cite

Age-related changes in memory CD4ϩ T cells (CD4) are poorly known. To address this issue, CD4 proliferative and cytokine responses to an anti-CD3 monoclonal (CD3), to cytomegalovirus (CMV), and to adenovirus (AdV) were assessed in 57 children (age, 0.07-17.16 y) and 17 adults. Results showed i) accumulation of memory CD4 with aging, with 2-3 times more centralmemory T cell (TCM; CD45RA Ϫ /CD62L ϩ ) than effector-memory T cell (TEM; CD45RA Ϫ /62L Ϫ ) CD4 at any age. ii) In children older than 2 y, CMV-specific CD4-secreting IFN␥ alone predominated over CD4-secreting IL2 ϩ IFN␥ and a continuous increase, with aging, in IFN␥ responses to the virus was observed. In contrast, in AdV infection, CD4-secreting IL2 ϩ IFN␥ predominated and IFN␥ responses to the virus reached adult levels from 3 y of age. iii) In children aged 0 -2 y, lower total IFN␥ responses to CMV (p Ͻ 0.02), AdV (p ϭ 0.05), and CD3 (p Ͻ 0.01) and lower IFN␥ ϩ IL2-responses (p ϭ 0.1, p Ͻ 0.02, p Ͻ 0.05, respectively) contrasted with no decrease in CD4-secreting IFN␥ alone. Defective proliferative responses to AdV (p ϭ 0.03) were also observed. In conclusion, the development of memory CD4 differed in acute AdV and persistent CMV infections. Young age seemed to depress mostly polyfunctional (IL2 ϩ IFN␥ secreting) CD4 in both infections. (Pediatr Res 69: 106-111, 2011)

show abstract

Section: Dynamic Changes In the Proportion Of Cd4mentioning

confidence: 58%

“…These two viruses were selected because virtually all children encounter AdV (14,15) and ϳ50% encounter CMV during childhood in our region (this article). CMV is a prevalent ␤-herpes virus that establishes lifelong infections after encountering the virus at birth or during childhood or adulthood.…”

mentioning

confidence: 99%

Development of Cytomegalovirus and Adenovirus-Specific Memory CD4 T-Cell Functions From Birth to Adulthood

et al. 2011

View full text Add to dashboard Cite

show abstract

“…However, a critical concern of the human Ad5 vector-based vaccines was the commonly existed pre-existing immunity (PEI) to human Ad5 with a baseline positive rate of 60-90% in the populations, which may compromise the effectiveness of the Ad5 vectored vaccine in inducing humoral and cellular immunogenicity. 25 Thus some scientists had tried to replace the human Ad5 vector with other less common human adenovirus such as Ad26 and Ad35, which exhibited a low pre-existing antibody in humans. [26][27][28] In 2011, a NHPs challenging study with a primeboost regimen using heterologous Ad26-vectored and Ad35-vectored Ebola vaccines demonstrated a significant protection after challenging with 1000 PFU of EBOV 28 (Table 3).…”

Section: Non-replicative Vector-based Ebola Vaccinesmentioning

confidence: 99%

Ebola vaccines in clinical trial: The promising candidates

Wang

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Ebola virus disease (EVD) has become a great threat to humans across the world in recent years. The 2014 Ebola epidemic in West Africa caused numerous deaths and attracted worldwide attentions. Since no specific drugs and treatments against EVD was available, vaccination was considered as the most promising and effective method of controlling this epidemic. So far, 7 vaccine candidates had been developed and evaluated through clinical trials. Among them, the recombinant vesicular stomatitis virusbased vaccine (rVSV-EBOV) is the most promising candidate, which demonstrated a significant protection against EVD in phase III clinical trial. However, several concerns were still associated with the Ebola vaccine candidates, including the safety profile in some particular populations, the immunization schedule for emergency vaccination, and the persistence of the protection. We retrospectively reviewed the current development of Ebola vaccines and discussed issues and challenges remaining to be investigated in the future.

show abstract

“…However, the Step results did spur interest in the development of adenoviral vectors from both human and nonhuman primate adenoviruses with a lower global prevalence of preexisting nAbsso-called rare serotype adenoviral vectorsas substitutes for Ad5. Rich debate continues on predicting the utility of these rare serotype adenoviral vectors based on typespecific nAb prevalence (16,17).…”

Section: Hiv Vaccine Approachesmentioning

confidence: 99%

Rare serotype adenoviral vectors for HIV vaccine development

Michael

2012

J. Clin. Invest.

View full text Add to dashboard Cite

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

Cited by 255 publications

References 34 publications

Development of Cytomegalovirus and Adenovirus-Specific Memory CD4 T-Cell Functions From Birth to Adulthood

Development of Cytomegalovirus and Adenovirus-Specific Memory CD4 T-Cell Functions From Birth to Adulthood

Ebola vaccines in clinical trial: The promising candidates

Rare serotype adenoviral vectors for HIV vaccine development

Contact Info

Product

Resources

About